BLR&D Research Career Scientist Award Application
BLR
基本信息
- 批准号:10047692
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-10-01 至 2022-09-30
- 项目状态:已结题
- 来源:
- 关键词:Adriamycin PFSAffectAgeAmerican Cancer SocietyAngiotensinsApoptosisApoptosis Regulation GeneAreaAtherosclerosisAttenuatedAwardBindingBiologicalBrainBreastBreast Cancer CellBreast Epithelial CellsCancer Cell GrowthCancer EtiologyCarcinogensCardiac Catheterization ProceduresCardiovascular DiseasesCardiovascular systemCell modelCellsCessation of lifeChemicalsChemoresistanceChemotherapy-Oncologic ProcedureChronicChronic DiseaseClinicClinicalCollaborationsCouples TherapyDNA Sequence AlterationDepressed moodDevelopmentDiagnosisDiseaseDrug resistanceEndothelinEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErlotinibEtoposideExposure toFemaleFormulationFoundationsFundingFutureGefitinibGeneral PopulationGoalsGrowthHealthHealthcareHealthcare SystemsHeart DiseasesHigh PrevalenceHormonesHumanHypertensionIncidenceIndividualInflammationKidneyKnowledgeLaboratoriesLipidsMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMedical Care CostsMental DepressionMilitary PersonnelMineralocorticoid ReceptorMissionModalityModelingMolecularMorbidity - disease rateMutationMyocardial InfarctionNano deliveryNeuronsNon-Small-Cell Lung CarcinomaNonmetastaticOccupational ExposureOncogenicPatientsPlayPrevalenceProcessProteinsPublicationsQuality of lifeReceptor Protein-Tyrosine KinasesRegulationRelapseRenal Artery StenosisRenovascular HypertensionResearchResearch ActivityResearch PersonnelResearch Project GrantsResistanceRheumatoid ArthritisRiskRodent ModelRoleScientistSeminalServicesSignal TransductionSocioeconomic StatusSteroidsStimulusStressStrokeSystemic hypertensionTestingTherapeuticThyroid GlandTimeTreatment FailureTyrosine Kinase InhibitorVariantVasopressinsVeteransWomanWomen&aposs Healthacute stressanti-cancerbehavioral responsebiological adaptation to stresscancer cellcardiovascular risk factorcareercell growthcombatdepression modeldesigneffective therapyfallshealingheart functionhuman old age (65+)improvedimproved outcomein vivokidney vascular structureknockout genelapatinibmalignant breast neoplasmmeetingsmenmimeticsmortalitymortality risknanonovelnovel therapeutic interventionparaventricular nucleuspreclinical studyproductivity lossprogramsreceptorresearch and developmentresponseservice membersmall moleculesmoking prevalencesuccesstargeted treatmenttherapy outcometherapy resistanttriple-negative invasive breast carcinoma
项目摘要
Inflammation is the body's attempt at self-protection to remove harmful stimuli and begin the healing process.
Chronic inflammation can eventually cause several diseases and conditions, including cancers, rheumatoid
arthritis, atherosclerosis, and plays a role in heart disease. The overarching goals of nominee’s research
involve elucidating molecular underpinnings of cell growth/survival and death/apoptosis with particular
reference cancer, atheroscleroscosis, and cardiovascular hypertension.
The American Cancer Society estimates highest percent of new cases and mortality resulting from lung and
breast cancers in females, while prostate and lung cancers account for highest percentage of new cases and
associated mortality among men. Overall incidence rates and mortality due to lung and breast cancers have
decreased over last decade partly due to advances in diagnosis and therapeutic modalities, particularly
targeted therapeutics for a number of cancers including the non-small cell lung cancers (NSCLCs). However,
adaptive genetic alterations and mutations in cancers contribute to therapy failures and relapses in clinic occur
that often result in emergence of resistant, hard to treat disease, and warrant development of new therapeutic
strategies to overcome drug resistance and improve therapeutic outcomes.
By utilizing a functional gene-knockout approach the nominee identified a novel, apoptosis inducing protein
termed CARP-1/CCAR1 (J. Biol. Chem. 278: 33422-33435, 2003). CARP-1 regulates apoptosis signaling
induced by diverse chemotherapeutics such as Adriamycin, Etoposide, and Gefitinib (reviewed by nominee in
Oncotarget 6(9): 6499-510, 2015). Following CARP-1 discovery, the nominee conducted a chemical-biological
approach to identify novel small molecule CARP-1 Functional Mimetic (CFMs) compounds (J. Biol. Chem. 286
(44): 38000-38017, 2011). CFMs inhibit growth diverse cancer cells including therapy-resistant triple-negative
breast cancers (TNBC) and non-small cell lung cancers (NSCLCs) in part by binding with CARP-1, causing
elevated levels of CARP-1 and apoptosis (Oncotarget, 2016, in press). The nominee’s long-term goal is to
elucidate molecular mechanisms of therapy resistance in cellular models of resistant TNBC and NSCLCs, and
utilize this knowledge to develop novel, safer and effective anti-cancer modalities. In this context CFMs or their
derivatives are anticipated to have clinical utility, and could provide novel means to develop future strategies
for effective treatment of TNBC, NSCLCs, and other cancers in the VA healthcare system and beyond.
Hypertension is a major health issue in the U.S., and the prevalence of atheros clerotic reno-vascular
hypertension is rising. Renal artery stenosis occurs in 28% of veterans undergoing cardiac catheterization with
a greater than 3-fold risk in those over age 65. Nonetheless, there is an alarming burden of cardiovascular and
renal morbidity and mortality with attendant increases in direct medical costs, loss of productivity and quality of
life in our Veterans with hypertension. The nominee has a productive collaboration with Detroit VA clinician-
scientist to study the molecular mechanisms of the hypertension. Since CARP-1 is also a co-activator of the
signaling by the steroid-thyroid receptors (Molecular Cell 31: 510-519, 2008), and with the knowledge that
mineralocorticoid receptor is known to play an important role in reno-vascular signaling, a potential overlap of
CARP-1 functions in this model was envisioned. Moreover, the fact that anti-cancer chemotherapies often
affect cardiac functions in patients, the nominee initiated this collaboration to study overlapping as well as
specific, perhaps, novel aspects of the angiotensin-endothelin signaling in Reno-vascular model. Although this
hypothesis has yet to tested, the nominee has thus far contributed in publication of an abstract in a national
meeting and is serving as a co-investigator of the two current VA funded Merit applications that focus on
investigating mechanisms of reno-vascular hypertension.
炎症是身体自我保护的一种尝试,以消除有害的刺激,并开始愈合过程。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Arun Kumar Rishi其他文献
Arun Kumar Rishi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Arun Kumar Rishi', 18)}}的其他基金
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
10356047 - 财政年份:2021
- 资助金额:
-- - 项目类别:
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
10618778 - 财政年份:2021
- 资助金额:
-- - 项目类别:
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
8598030 - 财政年份:2012
- 资助金额:
-- - 项目类别:
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
10025565 - 财政年份:2012
- 资助金额:
-- - 项目类别:
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
8392106 - 财政年份:2012
- 资助金额:
-- - 项目类别:
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
8141847 - 财政年份:2012
- 资助金额:
-- - 项目类别:
CARP-1: A Potential Therapeutic Agent for Breast Cancer
CARP-1:乳腺癌的潜在治疗剂
- 批准号:
8922216 - 财政年份:2012
- 资助金额:
-- - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
- 批准号:
2601817 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
- 批准号:
2029039 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
- 批准号:
9888417 - 财政年份:2019
- 资助金额:
-- - 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
- 批准号:
17K11318 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
-- - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
-- - 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
- 批准号:
BB/M50306X/1 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
- 批准号:
288272 - 财政年份:2013
- 资助金额:
-- - 项目类别:
Miscellaneous Programs














{{item.name}}会员




